Thermogenesis Holdings: Rises on plans to develop COVID-19 test kit
** Shares of cell-based therapy co THMO.O more than double
to $6.10 - set for biggest one-day pct jump in over 3 yrs
** Co says working with ImmuneCyte to develop, register,
import and seek U.S. FDA approval for an advanced point-of-care
test to diagnose COVID-19
** Separately, co reports a 35% rise in 2019 net revenue to
$13 mln, helped by demand for its cell therapy products AXP and
CAR-TXpress urn:newsml:reuters.com:*:nPn3J5lPya
** Including session's gain, THMO has risen ~42% YTD
(Reporting by Vishwadha Chander in Bengaluru)
((vishwadha.chander@thomsonreuters.com))
Recent news on Thermogenesis Holdings
See all newsThermogenesis Holdings Inc expected to post earnings of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc reports results for the quarter ended in December - Earnings Summary
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Thermogenesis Holdings Inc expected to post a loss of 1 cent a share - Earnings Preview
Brief: Thermogenesis Holdings Says On Jan 8 Co Received Nasdaq Letter Notifying It No Longer Complies With Minimum Bid Price Requirement For Listing On Nasdaq